PARP1 and ovarian carcinoma: Interestingly, a recent study has reported a correlation between therapeutic response to PARP inhibition and the patterns of ADP-ribosylation (i.e., amount of PARylation) in a panel of ovarian cancers, suggesting that ADP-ribosylation may be a useful biomarker for HR deficiency and sensitivity to PARP inhibitors regardless of BRCA status [31].